AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS
OwnerLuigi ANASTASIA, Adriana TARANTINO +3inventors
InventorsLuigi ANASTASIA, Adriana TARANTINO, Andrea GHIROLDI, Giuseppe CICONTE, Carlo PAPPONE
Life of this patent
Estimating the term…
Abstract
The present invention relates to autoantibodies against NaV1.5 channel, their use as biomarker for the diagnosis of Brugada syndrome in human beings and relative methods of detection and therapeutic approaches to target this new discovered form of autoimmunity.
Claims23
Autoantibodies directed against NaV 1.5 channel (SEQ ID NO:1) being biomarkers for the diagnosis of Brugada Syndrome in a human being.
A therapeutic method of treating Brugada Syndrome comprising the step of administering an immunomodulating or immunosuppressing drug non-specifically targeting the immune response against NaV1.5 by blocking antibody responses in a patient selected from the group consisting of Rituximab, Ocrelizumab, Ofatumumab, Inebilizumab Prednisone, Methylprednisolone, Dexamethasone, Colchicine and Hydroxychloroquine.
A kit for detecting autoantibodies against NaV 1.5 channel in a biological sample, the kit comprising one or more antigens that specifically binds to the autoantibodies against NaV 1.5 channel (SEQ ID NO:1).
An antigenic fragment of the extracellular loop of NaV 1.5 channel selected from the group consisting of the sequences SEQ ID NO:2-SEQ ID NO:7.
Dependencies are inferred from the claim text.